2. Search Result
Search Result
Results for "

Glycosyltransferase Inhibitors

" in MedChemExpress (MCE) Product Catalog:

6

Inhibitors & Agonists

1

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-148596
    UDP-GlcNAc

    UDP-N-Acetyl-D-glucosamine; Uridine diphospho-N-acetylglucosamine; UDP-N-acetylglucosamine

    		 Endogenous Metabolite P2Y Receptor Drug Intermediate Glycosyltransferase Infection
    UDP-GlcNAc (UDP-N-Acetyl-D-glucosamine) is an important component and precursor of bacterial peptidoglycan. UDP-GlcNAc is a nucleotide sugar used by Glycosyltransferases to synthesize glycoproteins, glycosaminoglycans, glycolipids, and glycoRNA. UDP-GlcNAc also serves as the donor substrate for forming O-GlcNAc, a dynamic intracellular protein modification involved in diverse signaling and disease processes. UDP-GlcNAc is the sugar nucleotide donor for the synthesis of O-GlcNAc modified proteins. UDP-GlcNAc also acts as a full agonist of the P2Y14 receptor and inhibits the formation of cAMP. UDP-GlcNAc can be used in studies related to bacterial infections .
    UDP-GlcNAc
  • HY-147960
    Glycosyltransferase-IN-1

    		Glycosyltransferase Infection
    Glycosyltransferase-IN-1 (compound 5m) is a potent glycosyltransferase inhibitor, with an IC50 of 82.8 μM. Glycosyltransferase-IN-1 shows antibacterial activity, with MIC values of 6 μg/mL for MSSA, MRSA, B. subtilis and 12 μg/mL for E. coli .
    Glycosyltransferase-IN-1
  • HY-163121
    PST3.1a

    		Glycosyltransferase TGF-β Receptor FAK Galectin Collagen Endocrinology Cancer
    PST3.1a is an orally active and brain-penetrant N-acetylglucosamine glycosyltransferase (MGAT5) inhibitor with a human IC50 of 2 µM. PST3.1a inhibits TGFβR and FAK signaling pathway activity. PST3.1a alters β1,6-GlcNAc N-glycans and microtubule/microfilament integrity, increases OLIG2 expression, and inhibits proliferation, migration, invasiveness, and clonogenic capacities of glioblastoma initiating cells. PST3.1a reduces invasive and proliferative capacity of glioblastoma initiating cells in orthotopic graft models, increases overall survival of orthotopic graft model mice. PST3.1a blunts MGAT5 overexpression, decreases renal fibrosis via collagen 1, collagen 4, and galectin 3 downregulation in a rat chronic kidney disease model. PST3.1a can be used for the research of glioblastoma multiforme and chronic kidney disease .
    PST3.1a
  • HY-175697
    Glycosyltransferase-IN-2

    		Glycosyltransferase SARS-CoV Angiotensin-converting Enzyme (ACE) DNA/RNA Synthesis Infection
    Glycosyltransferase-IN-2 (Compound 20) is a Glycosyltransferase inhibitor. Glycosyltransferase-IN-2 has a broad-spectrum anticoronavirus activity with IC50s of 11.3, 5.5 and ~16.2 μM for MHV, HCoV-NL63 and SARS-CoV-2, respectively. Glycosyltransferase-IN-2 interferes with the coronavirus infectivity, alters viral protein glycosylation with inhibition of interaction with the ACE2 receptor or SC-VLP secretion, and inhibits RNA replication. Glycosyltransferase-IN-2 can be used for coronavirus infections research .
    Glycosyltransferase-IN-2
  • HY-155716
    G43-C3-TEG

    		Bacterial Glucosylceramide Synthase (GCS) Infection
    G43-C3-TEG is a glycosyl-transferase inhibitor. G43-C3-TEG reduces the biofilm formation by decreasing the production of EPS (extracellular polysaccharides) .
    G43-C3-TEG
  • HY-E70291
    N-Acetylgalactosaminyltransferase 4

    GALNT4

    		 MAP3K p38 MAPK JNK NF-κB Endogenous Metabolite Cancer
    N-Acetylgalactosaminyltransferase 4 (GALNT4) is a glycosyltransferase capable of inhibiting the activation of ASK1. By directly binding to ASK1, N-Acetylgalactosaminyltransferase 4 suppresses its N-terminal dimerization and subsequent phosphorylation, leading to robust inactivation of downstream JNK/p38 and NF-κB signals, and thereby improving the prognosis of liver surgery .
    N-Acetylgalactosaminyltransferase 4

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: